Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 202

1.
2.

Comparison of caspofungin and amphotericin B for invasive candidiasis.

Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J; Caspofungin Invasive Candidiasis Study Group.

N Engl J Med. 2002 Dec 19;347(25):2020-9.

3.

Successful treatment of Candida krusei fungemia with amphotericin B and caspofungin.

Olver WJ, Scott F, Shankland GS.

Med Mycol. 2006 Nov;44(7):655-7.

PMID:
17071561
5.

Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis.

Golan Y, Wolf MP, Pauker SG, Wong JB, Hadley S.

Ann Intern Med. 2005 Dec 20;143(12):857-69.

PMID:
16365467
6.

Candida krusei fungemia in an unrelated allogeneic hematopoietic stem cell transplant patient successfully treated with Caspofungin.

Fanci R, Guidi S, Bonolis M, Bosi A.

Bone Marrow Transplant. 2005 Jun;35(12):1215-6. No abstract available.

PMID:
15852027
7.

Caspofungin in a pediatric patient with persistent candidemia.

Wertz KK, Pretzlaff RK.

Pediatr Crit Care Med. 2004 Mar;5(2):181-3.

PMID:
14987350
8.
9.

Invasive candidiasis in cancer patients: observations from a randomized clinical trial.

DiNubile MJ, Hille D, Sable CA, Kartsonis NA.

J Infect. 2005 Jun;50(5):443-9.

PMID:
15907554
10.

Successful treatment with caspofungin of refractory Candida krusei candidemia in a very low birth weight preterm infant.

Natale F, Castronovo A, Regoli D, De Curtis M, Manzoni P.

Pediatr Infect Dis J. 2009 May;28(5):452. doi: 10.1097/INF.0b013e31819d1cf1. No abstract available.

PMID:
19295457
11.

Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis.

Colombo AL, Perfect J, DiNubile M, Bartizal K, Motyl M, Hicks P, Lupinacci R, Sable C, Kartsonis N.

Eur J Clin Microbiol Infect Dis. 2003 Aug;22(8):470-4. Epub 2003 Jul 23.

PMID:
12884068
12.

Echinocandins--an advance in the primary treatment of invasive candidiasis.

Walsh TJ.

N Engl J Med. 2002 Dec 19;347(25):2070-2. No abstract available. Erratum in: N Engl J Med. 2006 Mar 16;354(11):1215.

PMID:
12490691
13.

Caspofungin versus amphotericin B for invasive candidiasis.

Brown AL, Greig JR.

N Engl J Med. 2003 Mar 27;348(13):1287-8; author reply 1287-8. No abstract available.

14.
15.

Combination therapy with caspofungin and liposomal amphotericin B for invasive aspergillosis.

Elanjikal Z, Sörensen J, Schmidt H, Dupuis W, Tintelnot K, Jautzke G, Klingebiel T, Lehrnbecher T.

Pediatr Infect Dis J. 2003 Jul;22(7):653-6.

PMID:
12867844
16.

Development of candidemia on caspofungin therapy: a case report.

Cheung C, Guo Y, Gialanella P, Feldmesser M.

Infection. 2006 Dec;34(6):345-8.

PMID:
17180591
17.

Caspofungin in combination with amphotericin B against Candida glabrata.

Barchiesi F, Spreghini E, Fothergill AW, Arzeni D, Greganti G, Giannini D, Rinaldi MG, Scalise G.

Antimicrob Agents Chemother. 2005 Jun;49(6):2546-9.

18.

Triple antifungal therapy for severe systemic candidiasis allowed performance of allogeneic stem cell transplantation.

Gahn B, Schub N, Repp R, Gramatzki M.

Eur J Med Res. 2007 Aug 16;12(8):337-40.

PMID:
17933709
19.

Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate.

Goodman D, Pamer E, Jakubowski A, Morris C, Sepkowitz K.

Clin Infect Dis. 2002 Aug 1;35(3):E35-6. Epub 2002 Jun 27.

PMID:
12115115
20.

Antifungal resistance: the clinical front.

Perfect JR.

Oncology (Williston Park). 2004 Dec;18(14 Suppl 13):15-22. Review.

Supplemental Content

Support Center